News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pressure Point Inc. Release: Story Optimal Antiemetic Non-Drug Substitute For Postoperative Nausea And Vomiting (PONV) Management



8/2/2017 12:03:26 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Optimal Antiemetic Non-Drug Substitute for Postoperative Nausea and Vomiting (PONV) Management Use Solving the Protracted PONV Problem with Pressure-Applied Therapy Pressure Point Inc.,

Tinton Falls, NJ, announces an antiemetic non-drug substitute having the capacity to increase optimal PONV containment for surgical patients. The additive effects of the company’s antiemetic substitute of pressure-driven therapy acts as a non-pharmacologic agent to control the physiology of PONV. As a disposable device its continuing effect removes the immediate concerns of early and late nausea and vomiting after surgery.

As part of routine PONV therapy, the company’s Pressure Right® antiemetic non-pharmacologic device may be used on a singular basis (moderate risk) or as an adjunct therapy (high risk) adult patients 18 years and older.

The company’s (non-sterile) antiemetic non-pharmacologic substitute device provides 72-hours of comfortable and uninterrupted pressure therapy stimulation to provide essential and timely PONV optimal prevention without drug-related adverse side effects.

We are seeking worldwide distribution sources, headed up by individuals preferably having surgical or anesthesia experience, to join our global network of independent providers. Our company’s global medical non-pharmacologic substitute device (Pressure Right) represents an optimal change in PONV management healthcare solutions.

Contact Information:
Joseph DiLustro, CEO
Email: therapeutics101@verizon.net
Phone/Text: (908) 601-8877
Website: www.pressurerightstrips.com

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES